跳至主要内容
临床试验/CTRI/2017/03/008158
CTRI/2017/03/008158尚未招募未知

A Randomized, Double-Blinded, Placebo-Controlled, Observational Pilot Study to assess the Safety and Efficacy of Stay-On oral liquid for prospective sexual function

SHREE MARUTI HERBA0 个研究点目标入组 26 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
26

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Male married patients aging 21 â?? 55 years
  • 2.The patients who have erectile insufficiency, premature ejaculation or lower sex drive for at least 3 month.
  • 3.Subjects with controlled diabetes mellitus and/or hypertension on monotherapy or low dose combination therapy (accepted co-medication in obese and overweight subjects, for example, antidiabetic drug metformin and hypertension, for example, antihypertensive drug amlodipine, atenolol, perindopril).
  • 4.The subjects should be sexually active and in a monogamous relationship with their heterosexual partner. Men must be sexually active: A man is considered sexually active if he has been engaged in sexual activity with a partner during the past 4 weeks (at least once) and plans to be active until end of study (unless due to travel or other practical reasons).
  • 5.Erectile function (EF) domain scores of the International Index of Erectile Function (IIEF) questionnaire <= 18.
  • 6.Fluent and literate in local language with the ability to read, comprehend and record information on the IIEF-15 questionnaire.
  • 7.Able to swallow and retain oral medication.
  • 8.Cooperative and understanding skills.
  • 9.Patient willing to provide written informed consent.
  • 10.Patient willing to give specimen of semen
  • 11.Patients ready to abstain from using any drug other than Investigational Product for the treatment of the studied condition, except in emergencies, in which case the responsible party must be immediately notified.

排除标准

  • 1.History or evidence of prostate cancer
  • 2.Current or prior use of any drugs with anti-androgenic properties (e.g. spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, progestational agents) within the 6 months prior to visit 1 (screening).
  • 3.Current or 1 month prior use of PDE-5 inhibitors for Erectile Dysfunction, Anabolic steroids, Use of phyto-therapy for sexual dysfunction within 2 weeks prior to screening visit.
  • 4.Any recent major surgical procedures.
  • 5.Spinal cord injury
  • 6.Radical prostatectomy
  • 7.Radical pelvic surgery

研究者

发起方
SHREE MARUTI HERBA

相似试验

进行中(未招募)
1 期
The metastatic castration-resistant prostate cancer (mCRPC) patients with homologous recombination repair (HRR) gene alterations who have notprogressed after docetaxel therapymetastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-001205-73-ITIMPACT Therapeutics Inc.165
尚未招募
Unknown
Effectiveness and Safety of Cg-A1 Peptide in Patients with Muscle Atrophy
CTRI/2024/01/061919Caregen.Co., Ltd
进行中(未招募)
3 期
Study to Assess the Effects of Deglusterol on Fasting Glucose and Other Cardiometabolic Risk Factors in type 2 diabetes mellitus patients who are on Metformin + gliptin combination therapy.
CTRI/2024/01/062047Caregen Co., Ltd.
进行中(未招募)
3 期
Study to Assess the Effects of Deglusterol on Type 2 Diabetes Mellitus.
CTRI/2023/07/054724Caregen Co., Ltd.
进行中(未招募)
1 期
The metastatic castration-resistant prostate cancer (mCRPC) patients with homologous recombination repair (HRR) gene alterations who have not progressed after docetaxel therapymetastatic castration-resistant prostate cancer (mCRPC)MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-001205-73-BEIMPACT Therapeutics, Inc.660
Stay-On oral liquid for prospective sexual functio | 临床试验